These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9667278)

  • 1. Oral chemotherapy: rationale and future directions.
    DeMario MD; Ratain MJ
    J Clin Oncol; 1998 Jul; 16(7):2557-67. PubMed ID: 9667278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
    Terwogt JM; Schellens JH; Huinink WW; Beijnen JH
    Cancer Treat Rev; 1999 Apr; 25(2):83-101. PubMed ID: 10395834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.
    Stuurman FE; Nuijen B; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2013 Jun; 52(6):399-414. PubMed ID: 23420518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes: old drugs, new oral formulations.
    Jibodh RA; Lagas JS; Nuijen B; Beijnen JH; Schellens JH
    Eur J Pharmacol; 2013 Oct; 717(1-3):40-6. PubMed ID: 23660368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.
    Singh BN; Malhotra BK
    Clin Pharmacokinet; 2004; 43(15):1127-56. PubMed ID: 15568891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric micelles in oral chemotherapy.
    Bromberg L
    J Control Release; 2008 Jun; 128(2):99-112. PubMed ID: 18325619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis.
    Fong SY; Brandl M; Bauer-Brandl A
    Eur J Pharm Sci; 2015 Dec; 80():89-110. PubMed ID: 26296863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy and safety assessment of nano-oxaliplatin oral formulation prepared by novel Fat Employing Supercritical Nano System, the FESNS®.
    Kim YH; Lee SJ; Lee SH; Hahn M
    Pharm Dev Technol; 2012; 17(6):677-86. PubMed ID: 23216046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique.
    Sawicki E; Schellens JH; Beijnen JH; Nuijen B
    Cancer Treat Rev; 2016 Nov; 50():247-263. PubMed ID: 27776286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
    Liu C; Chen Z; Chen Y; Lu J; Li Y; Wang S; Wu G; Qian F
    Mol Pharm; 2016 Feb; 13(2):599-608. PubMed ID: 26709621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral cancer chemotherapy in paediatric patients: obstacles and potential for development and utilisation.
    Bleyer WA; Danielson MG
    Drugs; 1999; 58 Suppl 3():133-40. PubMed ID: 10711852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
    Navarro RP; Morrow T; Baran R
    Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Boosting the oral bioavailability of anticancer drugs through intentional drug-drug interactions.
    Eisenmann ED; Talebi Z; Sparreboom A; Baker SD
    Basic Clin Pharmacol Toxicol; 2022 Jan; 130 Suppl 1(Suppl 1):23-35. PubMed ID: 34117715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer oral therapy: emerging related issues.
    Banna GL; Collovà E; Gebbia V; Lipari H; Giuffrida P; Cavallaro S; Condorelli R; Buscarino C; Tralongo P; Ferraù F
    Cancer Treat Rev; 2010 Dec; 36(8):595-605. PubMed ID: 20570443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
    van Waterschoot RA; Lagas JS; Wagenaar E; van der Kruijssen CM; van Herwaarden AE; Song JY; Rooswinkel RW; van Tellingen O; Rosing H; Beijnen JH; Schinkel AH
    Cancer Res; 2009 Dec; 69(23):8996-9002. PubMed ID: 19920203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the changing paradigm in cancer treatment: oral chemotherapy.
    Aisner J
    Am J Health Syst Pharm; 2007 May; 64(9 Suppl 5):S4-7. PubMed ID: 17468157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacoeconomic aspects of oral cytostatic agents].
    Poquet Jornet JE; Carrera-Hueso FJ; Gasent Blesa JM; Peris Godoy M
    Farm Hosp; 2011 May; 35 Suppl 2():25-31. PubMed ID: 22445506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
    Bardelmeijer HA; van Tellingen O; Schellens JH; Beijnen JH
    Invest New Drugs; 2000 Aug; 18(3):231-41. PubMed ID: 10958591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.